BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1314626)

  • 1. Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor.
    Gurney H; Anderson H; Radford J; Potter MR; Swindell R; Steward W; Kamthan A; Chang J; Weiner J; Thatcher N
    Eur J Cancer; 1992; 28(1):105-12. PubMed ID: 1314626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human GM-CSF in small cell lung cancer: a phase I/II study.
    Anderson H; Gurney H; Thatcher N; Swindell R; Scarffe JH; Weiner J
    Recent Results Cancer Res; 1991; 121():155-61. PubMed ID: 1650015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
    J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.
    Bokemeyer C; Schmoll HJ; Metzner B; Beyer J; Illiger HJ; Kneba M; Ostermann H; Kynast B; Räth U; Poliwoda H
    Ann Hematol; 1993 Aug; 67(2):75-9. PubMed ID: 8347733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
    Havemann K; Klausmann M; Wolf M; Fischer JR; Drings P; Oster W
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S203-7. PubMed ID: 1665493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
    Thongprasert S
    J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.
    Herrmann F; Schulz G; Wieser M; Kolbe K; Nicolay U; Noack M; Lindemann A; Mertelsmann R
    Am J Med; 1990 Jun; 88(6):619-24. PubMed ID: 2189305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
    Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
    Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
    Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
    Lydaki E; Bolonaki E; Stiakaki E; Dimitriou H; Kalmantis T; Kalmanti M
    Pediatr Hematol Oncol; 1995; 12(6):551-8. PubMed ID: 8589000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
    Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
    Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
    Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
    J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
    Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
    Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease.
    Aglietta M; Montemurro F; Fagioli F; Volta C; Botto B; Cantonetti M; Racanelli V; Teofili L; Ferrara R; Amadori S; Castoldi GL; Dammacco F; Levis A
    Cancer; 2000 Jan; 88(2):454-60. PubMed ID: 10640980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
    Aglietta M; Monzeglio C; Pasquino P; Carnino F; Stern AC; Gavosto F
    Cancer; 1993 Nov; 72(10):2970-3. PubMed ID: 8221563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.